Rocket Pharmaceuticals, Inc.
RCKTNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $264.53M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $2.17$5.45
- Volume (live)
- -
- Avg. volume (3M)
- 2.26M
Rocket Pharmaceuticals (RCKT) Stock Price & Financial Analysis
Rocket Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $2.18 - $2.34 |
|---|---|
| 52-Week High | $5.45 |
| 52-Week Low | $2.17 |
| Open | $2.20 |
| Volume (last close) | 2.16M |
| Average Volume (3M) | 2.26M |
| 50-Day MA | $3.13 |
|---|---|
| 200-Day MA | $3.51 |
| 1-Year Change | −38.24% |
| Market Cap | 264.53M |
|---|---|
| Shares Outstanding | 114.51M |
| Price to Book (P/B) | 0.72 |
| EV/EBITDA | 8.15 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Rocket Pharmaceuticals at a Glance
As of the Oct 22, 2026 close, Rocket Pharmaceuticals (RCKT) has a market capitalization of $264.53M.
As of its latest reported balance sheet, it holds $224.51M in cash and securities against $24.80M of debt, a net cash position of $199.71M.
Rocket Pharmaceuticals does not currently pay a dividend.
The share price is down 38.2% over the past year. At $2.31 (the Oct 22, 2026 close) it sits near the bottom of its 52-week range of $2.17 to $5.45, below its 200-day moving average of $3.51.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $9.50, 311.3% above the Oct 22, 2026 close.
Frequently Asked Questions About Rocket Pharmaceuticals
What is the current stock price for RCKT?
As of the Oct 22, 2026 close, RCKT stock trades at $2.31. The 52-week range is $2.17–$5.45, with a day range of $2.18–$2.34.
What is the P/E ratio for RCKT?
The P/E ratio (Price-to-Earnings) for RCKT is shown in the Key Statistics section. This valuation metric helps compare Rocket Pharmaceuticals, Inc. to industry peers.
Does RCKT pay dividends?
Rocket Pharmaceuticals does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for RCKT?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for RCKT is Buy. The average 12-month price target is $9.50, a 311.3% upside from the Oct 22, 2026 close of $2.31.
What is the market cap of RCKT?
As of the Oct 22, 2026 close, Rocket Pharmaceuticals's market capitalization is $264.5M, classifying it as a micro-cap company. Rocket Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.